[A17-25] Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2017
Project no.:
A17-25
Commission:
Commission awarded on 01.06.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Indication:
Secondary hyperparathyroidism
Result of dossier assessment:
Added benefit not proven due to a lack of suitable data
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-53 | Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25 | Commission completed |